Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis

Gynecologic Oncology

Volumn 117, Issue 1, 2010, Pages 139-145

  Valachis, Antonis ^a,b   Polyzos, Nikolaos P ^a   Georgulias, Vassilis ^b   Mavroudis, Dimitris ^b   Mauri, Davide ^a,c  

^a PACMeR: Medical Oncology and Obstetrics and Gynaecology   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c General Hospital of Lamia   (Greece)

Author keywords

Adjuvant; Bisphosphonates; Breast cancer; Fractures

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

BIBLIOGRAPHIC DATABASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COCHRANE LIBRARY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG EFFICACY; FRACTURE; HUMAN; MEDLINE; META ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77949288236     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.12.001     Document Type: Review

References (36)

1. Pfeilschifter J., and Diel I.J. Osteoporosis due to cancer treatment: pathogenesis and management. J. Clin. Oncol. 18 (2000) 1570-1593
2. Shapiro C.L., Manola J., and Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J. Clin. Oncol. 19 (2001) 3306-3311
3. Delmas P.D., and Fontana A. Bone loss induced by cancer treatment and its management. Eur. J. Cancer. 34 (1998) 260-262
4. Eastell R., Hannon R.A., Cuzick J., Dowsett M., Clack G., and Adams J.E. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, alone or in combination (ATAC) trial (18233230). J. Bone Miner. Res. 21 (2006) 1215-1223
5. Mincey B.A., Duh M.S., Thomas S.K., Moyneur E., Marynchencko M., Boyce S.P., et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin. Breast Cancer 7 (2006) 127-132
6. Perez E.A., Josse R.G., Pritchard K.I., Ingle J.N., Martino S., Findlay B.P., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA. 17. J. Clin. Oncol. 24 (2006) 3629-3635
7. Coleman R.E., Banks L.M., Girgis S.I., Kilburn L.S., Vrdoljak E., Fox J., et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in post-menopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled study. Lancet. Oncol. 8 (2007) 119-127
8. Cummings S.R., Browner W.S., Bauer D., Stone K., Ensrud K., Jamal S., et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N. Engl. J. Med. 339 (1998) 733-738
9. Hoff A.O., and Gagel R.F. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston. Park) 19 (2005) 651-658
10. Aapro M., Abrahamsson P.A., Body J.J., Coleman R.E., Colomer R., Costa L., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann. Oncol. 19 (2008) 420-432
11. Lau J., Ioannidis J.P., and Schmid C.H. Quantitative synthesis in systematic reviews. Ann. Intern. Med. 127 (1997) 820-826
12. Pettiti D. Meta-analysis, Decision Analysis and Cost-Effectiveness Analysis. 2nd ed (1999), Oxford Univ. Press, New York
13. Brufsky A., Bosserman L., Caradonna R., Haley B., Jones M., Moore H., et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up. Breast Cancer Res. Treat. 106 Suppl. 1 (2007) S8 [Abstract 27]
14. Eidtmann H, Bundred NJ, DeBoer R, Llombart A, Davidson N, Neven P, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. 2008 San Antonio Breast Cancer Symposium, Abstract 44 (http://www.abstracts2view.com/sabcs/).
15. Greenspan S.L., Brufsky A., Lembersky B.C., Bhattacharya R., Vujevich K.T., Perera S., et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J. Clin. Oncol. 26 (2008) 2644-2652
16. Lester J.E., Dodwell D., Purohit O.P., Gutcher S.A., Ellis S.P., Thorpe R., et al. Prevention of anastrazole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin. Cancer Res. 14 (2008) 6336-6342
17. Mincey B.A., Dentchev T., Sloan J.A., Hines S.L., Perez E.A., Johnson D.B., et al. N03CC-a randomized, controlled, open-label trial of upfront vs. delayed zoledronic acid for prevention of bone loss in postmenopausal (PM) women with primary breast cancer (PBC) starting letrozole after tamoxifen. J. Clin. Oncol. 26 (2008 May 20) (Suppl) [abstract 564]
18. Van Poznak C., Hannon R., Clack G., Campone M., Mackey J.R., Apffelstaedt J., et al. Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE). Presented at: San Antonio Breast Cancer Symposium (2008) [Abstract 1137]
19. Schenk N., Lombart A., Frassoladti A., Neven P., Jerusalem G., Deleu I., et al. The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (Let). Eur. J. Cancer 5 Suppl. 5 (2007) 186-187 [Abstract 2008]
20. Shapiro C.L., Halabi S., Gibson G., Weckstein D.J., Kirshner J., Sikov W.M., et al. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who developed ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results of GALGB trial 79809. J. Clin. Oncol. 26 (2008 May 20) (Suppl) [abstract 512]
21. Hershman D.L., McMahon D.J., Crew K.D., Cremers S., Irani D., Cucchiara G., et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J. Clin. Oncol. 26 (2008) 4739-4745
22. Hines S.L., Mincey B.A., Sloan J.A., Thomas S.P., Chottiner E.G., Loprinzi C.L., et al. N02C1: a phase III randomized, placebo-controlled, double-blind trial of risedronate for prevention of bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer (BC). J. Clin. Oncol. 26 (2008 May 20) (Suppl) [abstract 525]
23. Gnant M., Mlineritsch B., Luschin-Ebengreuth G., Kainberger F., Kassmann H., Piswanger-Solkner J.D., et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 9 (2008) 840-849
24. Delmas P.D., Balena R., Confravreux E., Hardouin C., Hardy P., and Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J. Clin. Oncol. 15 (1997) 955-962
25. Fuleihan G.e.l.-H., Salamoun M., Mourad Y.A., Chehal A., Salem Z., Mahfoud Z., et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J. Clin. Endocrinol. Metab. 90 (2005) 3209-3214
26. Saarto T., Vehmanen L., Elomaa I., Valimaki M., Makela P., and Blomqvist C. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br. J. Cancer 84 (2001) 1047-1051
27. Vehmanen L., Saarto T., Elomaa I., Makela P., Valimaki M., and Blomqvist C. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur. J. Cancer 37 (2001) 2373-2378
28. Tevaarwerk A., Stewart J.A., Love R., Binkley N.C., Black S., Eickhoff J., et al. Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women with breast cancer. J. Clin. Oncol. 25 (2007 Jun 20) (18S) [Abstract 19558]
29. Saarto T., Blomqvist T., Virkkunen P., and Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J. Clin. Oncol. 19 (2001) 10-17
30. Kristensen B., Ejlertsen B., Mouridsen H.T., Jensen M.B., Andersen J., Bjerregaard B., et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol. 47 4 (2008) 740-746
31. Powles T., Paterson S., McCloskey E., Schein P., Scheffler B., Tidy A., et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Ca. Res. 8 (2006) R13
32. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Postlberger S., Menzel C., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360 (2009) 679-691
33. Chen Z., Maricic M., Bassford T.L., Pettinger M., Ritenbaugh C., Lopez A.M., et al. Fracture risk among breast cancer survivors. Results from the Women's Health Initiative Observational Study. Arch. Intern. Med. 165 (2005) 552-558
34. Johnell O., Kanis J.A., Oden A., Johansson H., De Laet C., et al. Predictive value of BMD for hip and other fractures. J. Bone Miner. Res. 20 (2005) 1185-1194
35. Bruning P.F., Pit M.J., de Jong-Bakker M., van den Ende A., Hart A., and van Enk A. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br. J. Cancer 61 (1990) 308-310
36. Parulekar W.R., Day A.G., Ottaway J.A., Shepherd L.E., Trudeau M.E., Bramwell V., et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA.5. J. Clin. Oncol. 23 (2005) 6002-6008